Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV.

Adult treatment panel-II Adult treatment panel-II was based on observational epidemiological review, lipoprotein metabolism, animal studies, and early clinical trials.[ 7 , 8 ] Pooling of data from early clinical trials revealed a definite trend towards reduced total mortality in patients with CHD but no clinical trial or meta-analysis showed reduction in total mortality in the primary prevention patients.[ 14 ] ATP-II recommended a cautious use of lipid lowering agents in primary prevention of CHD since benefits from pharmacological treatment of lower risk patients would diminish by increased relative risks and cost of the therapy.

also in 240 other papers